LGI1 and encephalitis: The risk of developing seizures was reported at up to 90% in patients with anti-leucine-rich glioma-inactivated 1 (anti-LGI1), anti-gamma-aminobutyric acid A or B (GABA A or B) antibody encephalitis and up to 80% in anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) [14–17].